Semaglutide Starter Program (GLP-1 Analogue) For Weight Loss 5mg *5 vials

Description

Semaglutide is derived from the naturally occurring peptide GLP-1, which is known to lower blood sugar levels and boost insulin production. Semaglutide is a GLP-1 agonist and works by increasing insulin release, lowering the amount of glucagon released, delaying gastric emptying and reducing appetite.

Semaglutide injection is used to treat type 2 diabetes. It is used together with diet and exercise to help control your blood sugar. This medicine is also used to lower the risk of heart attack, stroke, or death in patients with type 2 diabetes and heart or blood vessel disease.

More recently, Semaglutide has grown in popularity as an injectable weight-loss medication. The injection imitates GLP1 ?C a naturally occurring peptide in your body ?C which is released after you eat and signals to your brain that you are full. It also slows the rate at which the stomach empties after eating, which leads to feelings of fullness for longer.

What Is Semaglutide?

Semaglutide peptide is a synthetic glucagon-like peptide-1 (GLP-1) analog. GLP-1 peptide is an endogenous peptide hormone containing 30 amino acids. The primary potential of this compound is to enhance insulin production, reduce blood sugar levels, and conserve the pancreatic beta cells by stimulating insulin gene transcription. Additionally, the compound delays apparent gastric emptying and hence may suppress appetite. GLP-1 appears to profounding affect the most critical organs, including the heart, kidney, lungs, and liver. Semaglutide, as a GLP-1 receptor agonist, may possibly reduce insulin levels and glucose, reduce appetite, and induce weight loss.

How Semaglutide Works ?

Semaglutide is a glucagon-like peptide-1 (GLP-1) agonist,Semaglutide works to lower high blood sugar by increasing the amount of insulin that is released, lowering the amount of glucagon released and by delaying gastric emptying. Semaglutide also controls appetite and so helps you reduce the amount of food that you want to eat.

Semaglutide Effects or Medical uses

• Regulates Blood Sugar
  ?CSemaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
  Semaglutide is a glucagon-like peptide-1 receptor agonist. It increases the production of insulin, a hormone that lowers the blood sugar level.It also appears to enhance growth of ?? cells in the pancreas, which are the sites of insulin production. It also inhibits glucagon, which is a hormone that increases blood sugar.
• Weight loss Shuts Down Hunger Cues
  Whenever we eat food, the foods we??re eating actually activate the appetite centers in the brain. Under normal conditions, we??d feel full when we??re done eating. This happens due to the release of a gut hormone called GPL-1 that essentially shuts down the brain??s hunger cues. Some people don??t experience these cues because their bodies aren??t producing the levels of GPL-1 needed to make them feel full and satisfied.
  When semaglutide is injected, it mimics the GLP-1 hormone to affect the receptors that ??shut down?? feelings of hunger. That means that you??re experiencing complete fullness and satisfaction when either not eating or eating much less food than normal. Studies have found that taking semaglutide is associated with fewer food cravings, less hunger and better control of food intake. Taking semaglutide also results in a lower preference for high fat foods.
  For many people, using semaglutide weekly marks the end of cravings, frenzied eating, and constant feelings of hunger. may decrease appetite and cause weight loss.

Other uses for this medicine

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Semaglutide Side Effects

Semaglutide injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

1. nausea
2. vomiting
3. diarrhea
4. abdominal pain
5. constipation
6. heartburn
7. burping

IMPORTANT WARNING: Some side effects can be serious. If you experience any of these symptoms call your doctor immediately or get emergency medical treatment:

1. ongoing pain that begins in the upper left or middle of the stomach but may spread to the back, with or without vomiting
2. rash; itching; swelling of the eyes, face, mouth, tongue, or throat; or difficulty breathing or swallowing
3. decreased urination; or swelling of legs, ankles, or feet
4. vision changes
5. fainting or dizziness
6. pain in upper stomach; yellowing of skin or eyes; fever; or clay-colored stools (in those receiving semaglutide [Wegovy] for management of weight loss)
7. rapid heartbeat

Semaglutide injection may cause other side effects. Call your doctor if you have any unusual problems while using this medication.

If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration??s (FDA) MedWatch Adverse Event Reporting program online.

Before using Semaglutide

What special precautions should I follow Before Taking Semaglutide Injection?

1. tell your doctor if you have or have ever had pancreatitis (inflammation of the pancreas), diabetic retinopathy (damage to the eyes caused by diabetes), gallbladder disease, or kidney disease. Also tell your doctor if you have recently had diarrhea, nausea, or vomiting or if you cannot drink liquids by mouth, which may cause dehydration (loss of a large amount of body fluids).
2. tell your doctor if you plan to become pregnant. Your doctor may tell you to stop using semaglutide injection for 2 months before a planned pregnancy.
3. tell your doctor if you are pregnant or are breastfeeding. If you become pregnant while using semaglutide injection, call your doctor.
4. ask your doctor what to do if there is a large change in your diet, exercise, or weight; or if you get sick, develop an infection or fever, experience unusual stress, or are injured. These changes and conditions can affect your blood sugar and the amount of semaglutide injection you may need.
5. tell your doctor and pharmacist if you are allergic to semaglutide, albiglutide (Tanzeum; no longer available in the US), dulaglutide (Trulicity), exenatide (Bydureon, Byetta), liraglutide (Saxenda, Victoza), lixisenatide (Adlyxin, in Soliqua), any other medications, or any of the ingredients in semaglutide injection. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
6. tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. It is especially important to tell your doctor about all the medications you take by mouth because semaglutide may change the way your body absorbs these medications.
7. you should know that your mental health may change in unexpected ways and you may become suicidal (thinking about harming or killing yourself or planning or trying to do so) while you are using semaglutide injection for weight loss. You, your family, or your caregiver should call your doctor right away if you experience any of the following symptoms: depression; talking or thinking about wanting to hurt yourself or end your life; withdrawing from friends and family; preoccupation with death and dying; or any other unusual changes in behavior or mood. Be sure that your family or caregiver knows which symptoms may be serious so they can call the doctor if you are unable to seek treatment on your own.

Why Semaglutide Choice For Weight Loss ?

Helps You Feel Fuller?CThere??s also a second way that semaglutide makes it easier to lose weight by eating less. Semaglutide injections slow down the movement of food through the stomach. This gives your body more time to feel fuller on fewer calories. In addition, semaglutide injections help the pancreas release the proper amount of insulin to correspond with blood-sugar levels to create a stable, non-shaky feeling.
The end result is a strong reduction in appetite that allows you to feel full and energized while eating much less. It??s like going on a diet without actually realizing that you??re dieting.

What Is Semaglutide Brand Product?

Wegovy, Ozempic, Rybelsus are the brand Semaglutide product,Each of the different brands of semaglutide (Wegovy, Ozempic, Rybelus) are FDA approved for different conditions.

How To Use Semaglutide?

Usual Adult Dose for Diabetes Type 2

Oral Tablets:
Initial dose: 3 mg orally once a day for 30 days; then 7 mg orally once a day

• Titration: If additional glycemic control is needed after receiving 7 mg/day for at least 30 days, may increase to 14 mg orally once a day

Maintenance dose: 7 to 14 mg orally once a day
Maximum dose: 14 mg/day (taking two 7 mg tablets to achieve a 14 mg dose is not recommended)

Subcutaneous Administration:
Initial dose: 0.25 mg subcutaneously once a week for 4 weeks, then 0.5 mg subcutaneously once a week

• If additional glycemic control is needed after at least 4 weeks receiving 0.5 mg dose subcutaneously once a week, may increase to 1 mg subcutaneously once a week

Maintenance dose: 0.5 to 1 mg subcutaneously once a week
Maximum dose: 1 mg/week

Switching between Subcutaneous Administration and Oral Tablets:

• Patients receiving 14 mg orally once a day can be transitioned to 0.5 mg subcutaneously once a week; subcutaneous administration should start after last oral dose
• Patients receiving 0.5 mg subcutaneously once a week can be transitioned to 7 or 14 mg orally once a day; oral therapy should start up to 7 days after last subcutaneous injection
• No equivalent oral dose is recommended to replace a subcutaneous dose of 1 mg weekly

Comments:

• Doses of 0.25 mg subcutaneously once a week and 3 mg orally once a day are intended for treatment initiation and are not effective doses for glycemic control.
• This drug has not been studied in patients with a history of pancreatitis; other antidiabetic therapies should be considered in these patients.

Uses:

• As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
• To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease

Usual Adult Dose for Cardiovascular Risk Reduction

Oral Tablets:
Initial dose: 3 mg orally once a day for 30 days; then 7 mg orally once a day

• Titration: If additional glycemic control is needed after receiving 7 mg/day for at least 30 days, may increase to 14 mg orally once a day

Maintenance dose: 7 to 14 mg orally once a day
Maximum dose: 14 mg/day (taking two 7 mg tablets to achieve a 14 mg dose is not recommended)

Subcutaneous Administration:
Initial dose: 0.25 mg subcutaneously once a week for 4 weeks, then 0.5 mg subcutaneously once a week

• If additional glycemic control is needed after at least 4 weeks receiving 0.5 mg dose subcutaneously once a week, may increase to 1 mg subcutaneously once a week

Maintenance dose: 0.5 to 1 mg subcutaneously once a week
Maximum dose: 1 mg/week

Switching between Subcutaneous Administration and Oral Tablets:

• Patients receiving 14 mg orally once a day can be transitioned to 0.5 mg subcutaneously once a week; subcutaneous administration should start after last oral dose
• Patients receiving 0.5 mg subcutaneously once a week can be transitioned to 7 or 14 mg orally once a day; oral therapy should start up to 7 days after last subcutaneous injection
• No equivalent oral dose is recommended to replace a subcutaneous dose of 1 mg weekly

Comments:

• Doses of 0.25 mg subcutaneously once a week and 3 mg orally once a day are intended for treatment initiation and are not effective doses for glycemic control.
• This drug has not been studied in patients with a history of pancreatitis; other antidiabetic therapies should be considered in these patients.

Uses:

• As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
• To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease

Usual Adult Dose for Weight Loss

Initial Dose Escalation Schedule:

• Weeks 1 through 4: 0.25 mg subcutaneously once a week
• Weeks 5 through 8: 0.5 mg subcutaneously once a week
• Weeks 9 through 12: 1 mg subcutaneously once a week
• Weeks 13 through 16: 1.7 mg subcutaneously once a week

Maintenance Dose:

• Week 17 and onward: 2.4 mg subcutaneously once a week

Dosing Considerations:

• If dose escalation is not tolerated, consider delaying dose escalation for 4 weeks
• If the maintenance dose of 2.4 mg once a week is not tolerated, the dose can be temporarily decreased to 1.7 mg once a week for a maximum of 4 weeks
• After 4 weeks, increase dose back to 2.4 mg once a week; discontinue therapy if the patient cannot tolerate the maintenance dose of 2.4 mg once a week

Comments:

• or patients with type 2 diabetes, blood glucose should be monitored at baseline and during treatment.
• This drug should not be coadministered with other semaglutide-containing products or with any other GLP-1 receptor agonist.
• The safety and effectiveness of using this drug in combination with other weight loss products have not been established.
• This drug has not been studied in patients with a history of pancreatitis.

Uses:
As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater, OR 27 kg/m2 or greater in the presence of at least one weight-related comorbid condition such as hypertension, type 2 diabetes mellitus, or dyslipidemia.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

No adjustment recommended

Dose Adjustments

Concomitant use of an insulin secretagogue (e.g., sulfonylurea) or insulin increases the risk of hypoglycemia, including severe hypoglycemia

• A reduced dose of insulin secretagogue or insulin may be needed

Precautions

US BOXED WARNING: Risk of Thyroid C-Cell Tumors:

• In rodents, this drug causes dose-dependent and treatment-duration dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether this drug causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) in humans, as the human relevance has not been determined.
• This drug is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Counsel patients regarding the risk of MTC and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients receiving this drug.

CONTRAINDICATIONS:

• A prior serious hypersensitivity reaction to semaglutide or to any product excipients; serious

hypersensitivity reactions including anaphylaxis and angioedema have been reported (subcutaneous formulation)

• Hypersensitivity to active substance or any product components (oral formulation)
• Personal or family history of medullary thyroid carcinoma (MTC)
• Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

No adjustment recommended with ESRD; however, no specific data is available for dialysis

Other Comments

Administration advice:
Oral Tablets:

• Take orally with no more than 4 ounces of plain water at least 30 minutes before the first food, beverage, or other oral medications of the day; waiting less than 30 minutes or taking with food, beverages other than plain water will decrease the absorption of this drug; waiting more than 30 minutes to eat may increase the absorption of this drug
• Swallow tablet whole, do not split, crush or chew
• Taking two 7 mg tablets to achieve a 14 mg dose is not recommended

MISSED DOSE: If a dose is missed, skip the missed dose and resume regular schedule

Subcutaneous Injection:

• Administer subcutaneously once a week into the abdomen, thigh, or upper arm; use a different injection site each week when injecting in the same body region
• Administer on the same day each week; may give at any time of the day, with or without meals
• When administering with insulin, administer as separate injections; it is okay to give in the same body region, but the injections should not be adjacent to each other
• Never share a pen between patients, even if the needle is changed; do not reuse or share needles or syringes between patients as this presents a risk for transmission of blood-borne pathogens

What Should I Do If I Miss A Semaglutide Dose?

MISSED DOSE for TYPE 2 DIABETES:

• If a dose is missed, administer as soon as possible within 5 days after the missed dose; if more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day, resume regular once a week dosing
• Day of weekly administration may be changed as long as the time between doses is greater than 48 hours

MISSED DOSE for WEIGHT LOSS:

• If 1 dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer as soon as possible
• If one dose is missed and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose.; resume dosing on the regularly scheduled day of the week
• If more than 2 consecutive doses are missed, resume dosing as scheduled or, reinitiate following the dose escalation schedule, which may reduce the occurrence of gastrointestinal symptoms associated with reinitiation of treatment

What Happens If I Overdose?

In case of overdose, If you take too much Semaglutide, call your healthcare provider or seek medical advice promptly. Information is also available online at Poison Help If the victim has collapsed, had a seizure, has trouble breathing, or can??t be awakened, immediately call emergency services.

Semaglutide Storage &Disposal

• Before dilution,Store Semaglutide in a refrigerator at 2??C to 8??C (36??F to 46??F) and avoid frozen.
• If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30?C (86?F) for up to 21 days.
• Do not freeze Semaglutide. Do not use Semaglutide if frozen.
• Store Semaglutide in the original carton to protect from light.

What are similar medications to semaglutide?

Semaglutide belongs to the class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1 agonists). There are several other GLP-1 agonists that are similar to semaglutide in terms of their mechanism of action and therapeutic use for the treatment of type 2 diabetes. Some commonly used GLP-1 agonists include:

• Liraglutide (Victoza): Liraglutide is another GLP-1 agonist that is approved for the treatment of type 2 diabetes. It shares similarities with semaglutide in terms of efficacy in lowering blood glucose levels and promoting weight loss.
• Dulaglutide (Trulicity): Dulaglutide is a once-weekly GLP-1 agonist used for the management of type 2 diabetes. It has a similar mechanism of action to semaglutide and has demonstrated efficacy in improving glycemic control and promoting weight loss.
• Exenatide (Byetta, Bydureon): Exenatide is available in two formulations: immediate-release (Byetta) for twice-daily dosing and extended-release (Bydureon) for once-weekly dosing. It is also a GLP-1 agonist used in the treatment of type 2 diabetes.
• Albiglutide (Tanzeum): Albiglutide is a once-weekly GLP-1 agonist that was previously available for the treatment of type 2 diabetes. However, it has been withdrawn from the market in some countries.
• Lixisenatide (Adlyxin): Lixisenatide is a GLP-1 agonist administered once daily for the management of type 2 diabetes. It has a similar mechanism of action to semaglutide and other GLP-1 agonists.
• Tirzepatide (Tirzepatide): Tirzepatide is a It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist..
  These are just a few examples of GLP-1 agonists that are similar to semaglutide in terms of their mechanism of action and use for type 2 diabetes management. It??s important to note that the specific choice of GLP-1 agonist may depend on various factors such as individual

Semaglutide Summary

Semaglutide is a relatively new drug that has been shown to be just as effective at reducing body weight as certain weight loss surgeries.
The drug??s effects were uncovered during a clinical trial led by Professor Rachel Batterham at University College London (UCL) to evaluate the efficacy of this drug in weight management.

Semaglutide Reviews

The study reported an average weight loss of around 2.4 stone or 15.3kg was lost in the group of participants taking the drug, while those receiving the placebo (dummy drug) only lost an average of 0.4 stone or 2.6kg.

Moreover, within the group taking Semaglutide, 75% of those in the Semaglutide group lost over 10% of their body weight and more than 30% lost over 20% of their body weight.
The findings indicate that this may indeed represent a major breakthrough in improving the health of those living with obesity.

References : Learn more about Semaglutide

1. ??Semaglutide in Obesity: An Evidence-Based Review of the Potential Benefits and Risks.?? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270223/
2. ??Semaglutide for the Treatment of Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.?? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211464/
3. ??Efficacy and safety of semaglutide versus sitagliptin after 56 weeks in participants with type 2 diabetes inadequately controlled with metformin monotherapy.?? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287852/
4. ??Semaglutide and Weight Loss: A Systematic Review and Meta-Analysis.?? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930679/
5. ??Semaglutide in Type 2 Diabetes Mellitus: A Review of the SUSTAIN Trial Program.?? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776813/
6. FDA.gov Semaglutide: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
7. Wegovy Information: https://www.novo-pi.com/wegovy.pdf